Current tuberculosis vaccine development.
Information derived from the complete genome sequence of Mycobacterium tuberculosis makes it possible to develop a range of new vaccine candidates. Strategies currently under investigation include construction of whole cell live attenuated mycobacterial vaccines, as well as the use of individual antigens delivered by a variety of subunit vaccination procedures. Fundamental questions associated with the rational design, preclinical testing, and future application of new tuberculosis vaccines are reviewed.
Young
D B
DB
Department of Infectious Diseases and Microbiology, Imperial College School of Medicine, London, London W2 1PG, United Kingdom. d.young@ic.ac.uk.
D000818:Animals; D001500:BCG Vaccine / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology; D015195:Drug Design; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000235:genetics / Q000276:immunology*; D014397:Tuberculosis, Pulmonary / Q000276:immunology / Q000517:prevention & control*; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic / Q000276:immunology
D001500:BCG Vaccine; D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic